De Novo Vogt-Koyanagi-Harada Disease following Covid-19 Vaccine: A Case Report and Literature Overview.
Ocul Immunol Inflamm
; 30(5): 1292-1295, 2022 Jul.
Article
in English
| MEDLINE | ID: covidwho-1671885
ABSTRACT
PURPOSE:
To describe a case of Vogt-Koyanagi-Harada (VKH) disease after a Covid-19 mRNA vaccine (tozinameran) and to present the results of a pharmacovigilance disproportionality study.METHODS:
A retrospective chart review and a pharmacovigilance disproportionality study using the WHO global individual case safety reports database (VigiBase).RESULTS:
A 57-year-old female with no medical history developed a VKH disease 3 weeks after Covid-19 mRNA vaccine. Symptoms at onset were headaches and blurred vision associated with aseptic meningitis and bilateral diffuse granulomatous panuveitis with serous retinal detachment. One month from diagnosis and glucocorticoids treatment, the patient recovered. Five similar cases have been reported in VigiBase. VKH disease is disproportionately reported with tozinameran and other vaccines.CONCLUSION:
VKH disease is disproportionately reported with tozinameran, suggesting a possible safety signal. Cases after vaccination support the screening for any possible immune triggers such as vaccines when assessing patients with VKH disease.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Panuveitis
/
Uveomeningoencephalitic Syndrome
/
COVID-19
Type of study:
Case report
/
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
Ocul Immunol Inflamm
Journal subject:
Allergy and Immunology
/
Ophthalmology
Year:
2022
Document Type:
Article
Affiliation country:
09273948.2022.2028291
Similar
MEDLINE
...
LILACS
LIS